Article

Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 43, n° 4
pages 656-663 (octobre 2000)
Doi : 10.1067/mjd.2000.107938
accepted : 13 April 2000
Photodamage pilot study: A double-blind, vehicle-controlled study to assess the efficacy and safety of tazarotene 0.1% gel
 

John Sefton, PhD a, Albert M. Kligman, MD, PhD b, Scott C. Kopper, BS a, John C. Lue, MS a, John R. Gibson, MD a
Irvine, California, and Philadelphia, Pennsylvania 
From Allergan, Inc, Irvine,a and the Department of Dermatology, University of Pennsylvania College of Medicine, Philadelphia.b 

Abstract

Background: Tazarotene, a potent acetylenic retinoid for topical use, might be expected to benefit photodamaged skin, including improving the classical signs of fine wrinkles, mottled hyperpigmentation, and roughness. Objective: Our purpose was to determine the efficacy and safety of tazarotene 0.1% gel in the treatment of photodamaged dorsal forearm skin. Methods: Ten healthy female volunteers, aged 45 to 65 years, with moderately photodamaged forearm skin applied tazarotene 0.1% gel to one arm and vehicle gel to the other once daily for 12 weeks. The study was a double-blind, randomized, paired-comparison evaluation conducted at a single site. Results: Tazarotene showed beneficial effects for several efficacy variables. It was more efficacious than vehicle in reducing skin roughness and fine wrinkling based on objective measurements. Tazarotene also corrected epidermal atrophy and atypia and improved skin hydration properties. Conclusion: In this 12-week pilot study tazarotene redressed abnormalities associated with photo-damaged skin. (J Am Acad Dermatol 2000;43:656-63.)

The full text of this article is available in PDF format.

 Supported by Allergan, Inc.
 Reprint requests: John Sefton, PhD, Allergan, Inc, Skin Care Clinical R&D, 2525 Dupont Dr, Irvine, CA 92612. E-mail: sefton_john@ allergan.com.
 J Am Acad Dermatol 2000;43:619-26.



© 2000  American Academy of Dermatology, Inc. Published by Elsevier Masson SAS@@#104157@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline